Models

Dataset Information

254

Hartmann2016 - Blood coagulation model for simulating anticoagulants


ABSTRACT: Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).

SUBMITTER: Matthew Roberts  

PROVIDER: MODEL1807180004 | BioModels | 2018-07-18

REPOSITORIES: BioModels

altmetric image

Publications

Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Hartmann S S   Biliouris K K   Lesko L J LJ   Nowak-Göttl U U   Trame M N MN  

CPT: pharmacometrics & systems pharmacology 20160920 10


Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis. This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. A quantitative systems pharmaco  ...[more]

Similar Datasets

2018-06-07 | MODEL1806070001 | BioModels
2019-07-10 | BIOMD0000000747 | BioModels
2018-07-23 | MODEL1807230003 | BioModels
2018-07-24 | MODEL1807240002 | BioModels
2019-07-01 | BIOMD0000000739 | BioModels
2018-06-13 | MODEL1806130002 | BioModels
2018-07-18 | MODEL1807180001 | BioModels
2018-07-24 | MODEL1807240001 | BioModels
2018-06-13 | MODEL1806130001 | BioModels
2019-07-12 | MODEL1907120001 | BioModels